3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
11
Neoplasms
3
HER2-positive Breast Cancer
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Endometrial Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Hemangiosarcoma
1
HR+/HER2+ Early Breast Cancer
1
Glioma
1
Interventions
durvalumab
3
Fulvestrant
3
Cisplatin
3
pembrolizumab
2
abemaciclib
2
Pemetrexed
2
Carboplatin
2
ribociclib
1
repotrectinib
1
palbociclib
1
exemestane
1
enfortumab vedotin
1
elacestrant
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
STX-478
1
Radiation Dose Hypofractionation
1
RAD1901
1
Oviposition
1
Nivolumab
1
Mitomycin
1
Metformin
1
Letrozole
1
Immunotherapy
1
Imlunestrant
1
Gemcitabine
1
Fluorouracil
1
Drug Therapy
1
Drainage
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
pertuzumab
×
30 days
×
Clear all
No trials found.